2011
p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)
Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF, B F. p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905). Clinical Cancer Research 2011, 17: 5170-5178. PMID: 21693655, PMCID: PMC3149770, DOI: 10.1158/1078-0432.ccr-11-0484.Peer-Reviewed Original ResearchConceptsAddition of paclitaxelDoses of doxorubicinOverall survivalP53 protein expressionAdjuvant doxorubicinDose escalationBreast cancerP53 expressionNode-positive breast cancer patientsNode-positive breast cancerEarly-stage breast cancerCycles of cyclophosphamideNode-positive patientsProtein expressionStage II patientsBreast cancer patientsRandomized clinical trialsWorse RFSWorse OSII patientsPredictive factorsWorse prognosisCancer patientsP53 positivityP53 staining
2007
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. New England Journal Of Medicine 2007, 357: 1496-1506. PMID: 17928597, DOI: 10.1056/nejmoa071167.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor type 2Node-positive breast cancerAddition of paclitaxelEstrogen receptor statusHER2 positivityBreast cancerAdjuvant chemotherapyDoxorubicin dosesAdjuvant anthracycline-based chemotherapyEpidermal growth factor receptor type 2HER2-positive breast cancerFactor receptor type 2CB11 monoclonal antibodyCycles of paclitaxelAnthracycline-based chemotherapyAdministration of paclitaxelReceptor type 2Breast cancer cellsAdjuvant treatmentHazard ratioClinical outcomesPositive cancersHER2 amplificationImmunohistochemical analysisCyclophosphamide
2006
Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density
Abusief M, Missmer S, Ginsburg E, Weeks J, Winer E, Partridge A. Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density. Journal Of Clinical Oncology 2006, 24: 10506-10506. DOI: 10.1200/jco.2006.24.18_suppl.10506.Peer-Reviewed Original ResearchRisk of amenorrheaEarly breast cancerBreast cancerDDS therapyPremenopausal womenDana-Farber Cancer InstituteMultivariable logistic regression modelChemotherapy-related amenorrheaLikelihood of amenorrheaAddition of paclitaxelDose densityEffect of paclitaxelLogistic regression modelsAdjuvant chemotherapyTamoxifen useWomen's HospitalMultivariable modelMenstrual functioningAmenorrheaAverage ageCancer InstituteMenstrual dataPatientsAlcohol useTherapy